Cambium Biomaterials Inc.

Cambium Biomaterials Inc., headquartered in El Segundo, California, is a for-profit manufacturer specializing in advanced biomaterials and high-performance composites tailored for defense and military applications. The company has established itself as a capable prime contractor to the federal government, particularly the U.S. Navy's Office of Naval Research, through the development and supply of innovative protective systems and specialized materials. Cambium's core competency lies in biomaterial science combined with optical performance and thermal protection capabilities, positioning the company as a specialized supplier of cutting-edge defense-focused materials and systems.

Cambium Biomaterials has demonstrated substantial federal contracting activity across multiple weapon systems and defense technology initiatives. The company received a $9.15 million Other Transaction Agreement from the Office of Naval Research on September 10, 2025, for developing advanced biomaterial-based laser protection defense systems for optical sensor packages, with completion scheduled for September 9, 2027. Prior to this award, ONR issued a $4.41 million Other Transaction Agreement on September 27, 2024, for the development of biomaterial-based laser protective eyewear designed to enhance warfighter protection while maintaining visual acuity, with performance extending through November 26, 2025. The company also received a $4.735 million firm-fixed-price definitive contract from ONR on September 11, 2024, for advancing thermal protection systems for hypersonic missiles, completed by September 10, 2025. Additionally, Cambium secured a $348,491.06 sole-source definitive contract from Naval Air Warfare Center on June 16, 2022, involving resin synthesis, carbon fiber composite fabrication, and drone airframe assembly with testing for fire resistance and laser strike evaluation, completed December 16, 2022. Most recently, on December 31, 2024, the company received an $81,533.50 purchase order from ONR for the supply of P-100 phthalonitrile R&D grade monomers to support fabrication and testing of ablative and fire-resistant composites for Department of Defense applications. All contract awards were awarded without set-aside designations and represent ONR's investment in advanced material innovations supporting naval and broader military operational effectiveness.

Cambium Biomaterials received a federal grant sub-award from the Bioindustrial Manufacturing and Design Ecosystem program on January 3, 2023, designated as Detailed Research Project 6. This sub-award indicates the company's participation in broader federal research initiatives focused on advanced manufacturing and biomaterial design ecosystems, though specific details regarding the scope, funding level, and performance requirements of this sub-award were not provided in the available documentation.

Cambium Biomaterials holds an Other Transaction Indefinite Delivery Vehicle awarded by the Defense Advanced Research Projects Agency on August 14, 2025, with a ceiling value of $399,299.00 and no set-aside designation. This contract vehicle, titled "Titanium Replacement in Military Systems Through Artificial Intelligence," is designed to facilitate innovative research and development efforts focused on materials science applications that could reduce weight, cost, or improve performance characteristics of military platforms. The OT IDV structure enables flexible task order issuance and iterative development approaches, allowing DARPA to leverage Cambium's specialized expertise in composite materials and biomaterial engineering. The vehicle contemplates multiple future task orders within its ceiling value and aligns with DARPA's mission to maintain technological superiority through exploration of cutting-edge materials and computational design methodologies for defense applications. This IDV complements Cambium's existing portfolio of ONR contracts and demonstrates the company's expanded role in supporting broader Department of Defense innovation objectives across multiple research institutions and defense agencies.